Amgen Inc. Reports Key Financial Insights in 8-K Filing - November 2025

Based on the provided section of the financial report, here are the key insights and information extracted:

1. Entity Information:

• Company Name: Amgen Inc.
• CIK Number: 0000318154
• Address: One Amgen Center Drive, Thousand Oaks, CA 91320-1799
• Contact Number: 805-447-1000

2. SEC Filing Details:

• Filing Type: Form 8-K
• Filing Date: November 4, 2025

3. Stock Information:

• Common Stock: Par value of $0.0001
• Ticker Symbol: AMGN
• Exchange: NASDAQ

4. Debt Instruments:

• Type of Debt: 2.000% Senior Notes due 2026
• Ticker Symbol for Debt: AMGN26
• Exchange for Debt: NASDAQ

5. Reporting Period:

• The report covers a specific date: November 4, 2025.

6. Class of Stock:

• The stock class mentioned is "Common Stock".

7. Segment Information:

• The report involves multiple segments, including a class of stock (Common Stock) and a specific debt instrument (Senior Notes due 2026).

Insights:

• Amgen Inc. is actively managing its debt portfolio with the issuance of 2.000% Senior Notes due in 2026, indicating a focus on maintaining a favorable interest rate environment.
• The reporting date aligns with a significant corporate event, as indicated by the 8-K filing, which typically discloses major company developments that shareholders need to be aware of.
• The inclusion of detailed identifiers and exchange listings suggests a comprehensive compliance with SEC regulations, ensuring transparency and accessibility for investors.

Overall, this section emphasizes Amgen's financial instruments and its compliance with regulatory requirements, highlighting its operational activities as of the specified date.